Crizotinib safe, effective for ALK+ pediatric ALCL, IMTs

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • In children with advanced anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMTs), crizotinib (Xalkori) is safe and effective.

Why this matters

 

 

  • Advanced ALCL and IMTs have a poor prognosis.

Study design

 

 

  • In this phase 2 Children's Oncology Group trial, safety and efficacy of crizotinib were studied at different doses in 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT.
  • Response was defined by a positive response for a minimum of 2 consecutive imaging studies at least 4 wk apart.
  • Funding: National Cancer Institute, Pfizer, and Cookies for Kids Cancer Foundation.

Key results

 

 

  • 83% of patients with ALCL who received a dose of 165 mg/m2 responded and 90% of patients who received a dose of 280 mg/m2 responded.
  • Complete response was seen in 83% of the 165 mg/m2 group and 80% of the 280 mg/m2 group of patients with ALCL.
  • 86% of patients with IMT responded (doses of 100, 165, and 280 mg/m2).
  • A complete response was seen in 36% of patients with IMT.
  • The most frequent adverse event was a lowering of neutrophil count in 33%-70% patients of the ALCL group and 43% patients of IMT group.

Limitation

 

 

  • Small sample sizes.